Sarkar’s project examines the role of lymphangiogenesis – the process of lymphatic growth from preexisting lymphatic vessels – in the spread of breast cancer, with the ultimate aim to develop newer therapeutic approaches targeting lymphangiogenesis for treatment of breast cancer patients. Singh’s...
It's The Journey's flagship fundraising event is theGeorgia2-Day Walk for Breast Cancer. Since 2002, It's The Journey has funded 465 grants totaling over $17.5 million. Through our grantees, we touch tens of thousands of Georgians each year. We support women and men with screening, educa...
T-DXd Shows Promise in Treating HER2+ Breast Cancer With Brain Mets Ovarian Function Suppression Improves Survival in Premenopausal Women with HR+, HER2+ Breast Cancer A Closer Look at T-DXd in HER2-Positive Breast Cancer Navigating Treatment Options for HER2+ BC: A Need for CustomizationRelat...
The test, TriNetra, uses proprietary technology to detect Circulating Tumor Cells (CTCs) specific to breast cancer. In previous studies, the device detected Stage 0 and Stage 1 cancers with high accuracy. Specifically, TriNetra is approved for asymptomatic women over the age of 4...
For instance, women who are pregnant, postpartum or breastfeeding. Infants are eligible up to the infants’ first birthday. Children qualify up to the age of 5. WIC is designed as a short-term program, with eligible recipients usually receiving benefits for six (6) months to a year, at ...
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to Trodelvy ® for the treatment of adult patients with extensive-stage small cell lung cancer whose disease has progressed on
The FDA has granted breakthrough therapy designation to the DCISionRT test, a tool that assesses radiation therapy benefit for women aged 30 to 85 with ductal carcinoma in situ. The FDA has granted breakthrough therapy designation to the DCISionRT test for patients with ductal carcinoma in ...
Researching how metals and their transporters affect cancer cell behavior for novel therapeutic cancer treatments. About Mary Kay Then. Now. Always. One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives...
Chief Medical Officer, Gilead Sciences. “This achievement, coupled with last week’s full FDA approval in unresectable locally advanced or metastatic triple-negative breast cancer, underscores our commitment toward rapidly delivering Trodelvy to patients...
“The FDA’s acceptance of this application for priority review, as well as under the RTOR program, underscores the urgency to bring this treatment option that has demonstrated an OS benefit over chemotherapy to more patients with locally advanced or metastatic urothelial carcinoma,” said Dr. Elia...